Medivation (MDVN) : 14 analysts are covering Medivation (MDVN) and their average rating on the stock is 2.57, which is read as a Hold. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. A total of 11 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Medivation (MDVN) : The consensus price target for Medivation (MDVN) is $71.82 for the short term with a standard deviation of $12.35. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $82, however, the pessimist price target for the company is $40.
Company shares have received an average consensus rating of Hold for the current week Also, In the latest statement by the brokerage house, Citigroup downgrades its outlook on Medivation (NASDAQ:MDVN). The current rating of the shares is Hold, according to the research report released by the firm. Previously, the company had a rating of Buy. The brokerage firm raises the price target from $73 per share to $81.5 per share. The rating by the firm was issued on August 23, 2016.
Medivation (NASDAQ:MDVN): The stock opened at $80.84 and touched an intraday high of $80.97 on Wednesday. During the day, the stock corrected to an intraday low of $80.75, however, the bulls stepped in and pushed the price higher to close in the green at $80.97 with a gain of 0.16% for the day. The total traded volume for the day was 2,414,353. The stock had closed at $80.84 in the previous trading session.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.